MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bja.2026.05.004

Медицинская библиотека · British journal of anaesthesia · 2026

Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies.

Haziri Fisnik, Durak Koray, Glarner Noemi, Ergin Emre, Burri-Winkler Katrin, Kaplan Emel, Thommen Vanessa, Pargger Mirjam, Huré Gabrielle, Giger Rafael V, Bolliger Daniel, Steiner Luzius A, Mujagic Edin, Lardinois Didier, Schären Stefan, Mueller Andreas, Kunz Michael, Stolte Thorald, Mahfoud Felix, Strebel Ivo, Puelacher Christian, Gualandro Danielle M, Mueller Christian

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

International clinical practice guidelines recommend discontinuing sodium-glucose cotransporter-2 inhibitors (SGLT2i) 3-4 days before surgery to prevent euglycemic diabetic ketoacidosis, chiefly on the basis of case reports/series. Whether SGLT2i discontinuation may increase the risk of postoperative cardiovascular complications is unclear.

METHODS

In a secondary analysis of the Basel-PMI (NCT02573532) and PMI-Vital (NCT05866874) prospective cohort studies in major noncardiac surgery, the exposure of interest was continuing, or stopping, SGLT2i in participants receiving chronic SGLT2i therapy. The primary outcome was an ordinal composite of acute heart failure hospitalisation and cardiovascular death within 90 days of surgery, adjusting for prespecified covariates. Secondary outcomes included the incidence of euglycemic diabetic ketoacidosis within 7 days.

RESULTS

Among 451 study participants receiving SGLT2i (mean age 72 (range: 47-86) yr; 22% women), 404/451 (89.6%) had diabetes mellitus, and 166/451 (36.9%) had chronic heart failure. SGLT2i were discontinued before surgery in 393/451 (87.1%) participants (39.2% for 1 day, 34.4% for 2 days, 13.5% for ≥3 days). Cardiovascular complications occurred in 1/58 (1.7%) participants who continued SGLT2i, compared with 10/177 (5.7%) stopping for 1 day, 13/155 (8.4%) stopping for 2 days and 7/61 (11.5%) stopping for ≥3 days (P=0.011; adjusted odds ratio: 1.58 [95% confidence interval: 1.08-2.30] per discontinued day). Euglycemic diabetic ketoacidosis occurred in 1/451 participants after SGLT2i discontinuation.

CONCLUSIONS

Perioperative SGLT2i discontinuation was associated with a substantially increased risk of 90-day cardiac complications. This suggests potential harm in current guideline recommendations; randomised controlled trials are needed to confirm these findings.

STUDY REGISTRATION: NCT02573532, NCT05866874.

Для цитирования: Haziri Fisnik, Durak Koray, Glarner Noemi, Ergin Emre, Burri-Winkler Katrin, Kaplan Emel, Thommen Vanessa, Pargger Mirjam, Huré Gabrielle, Giger Rafael V, Bolliger Daniel, Steiner Luzius A, Mujagic Edin, Lardinois Didier, Schären Stefan, Mueller Andreas, Kunz Michael, Stolte Thorald, Mahfoud Felix, Strebel Ivo, Puelacher Christian, Gualandro Danielle M, Mueller Christian. Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies.. British journal of anaesthesia. 2026. DOI: 10.1016/j.bja.2026.05.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.